To test this hypothesis, we examined whether treating AD mice with the RyR-inhibitor dantrolene could stabilize Ca2+ signaling and synaptic transmission in AD mice while having minimal impact on these functions in normal non-transgenic mice. This evidence concerns the gene RYR1 and Alzheimer disease.